News Archive

Howard Carolan, Co-Founder and CEO  of CoapTech, Inc., and Neil Davis, Program Director of the Biomedical Entrepreneurship Graduate Certificate program at the University of Maryland Baltimore (UMB), joins Rich Bendis to discuss Startups, Tech Transfer, and the Funding.

Listen now on Google https://bit.ly/36fStWr, Apple https://apple.co/2UpA0UO, Spotify https://spoti.fi/36igrjG, and TuneIn https://bit.ly/3hpCRpT.

Mr. Davis is currently Program Director of the Biomedical Entrepreneurship graduate certificate program at the University of Maryland Baltimore (UMB).  This unique 12 credit graduate certificate provides the student with an opportunity to learn the process of creating valuable intellectual property (IP) and moving it into commercial application.  This process begins with the creation of IP, continues to its licensing and the formation of a venture through the growth of the venture, and culminates with the monetization of that venture.

Thanks to unprecedented development speed and mostly strong safety and efficacy data, vaccines have dominated the response to COVID-19. But ending the pandemic will also require development of numerous therapeutics.

Seven COVID-19 drugs have shown promise recently. Positive signs include the accumulation of encouraging data, participation in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) trials, and/or progress toward regulatory authorizations.

• This  document  has been  redacted by  Sam Collaudin, Kinexum Business Strategy  Consultant, independently  from any  pharmaceutical and  biotech companies 
• It synthesizes  selected  data presented  during  the  ATTD 2021  conference 
• Grey  rectangles  are  personal  comments and  opinions,  underlined  words are clickable  links  to other  slides  or  external  references 
• If  you  have comments, please  contact me by  email (samcollaudin@kinexum.com) 
• Disclosure: Business  strategy consultant  at Modular  Medical,  CEO  of Abvance Kinexum ,  consultant  for Therapeutics, chairman  of  a non  for profit French health  care  insurance company  (Groupe Operating  Since  2003 Uitsem)

The firm helps gene therapy and vaccine companies develop and manufacture products for rare diseases.

Image: Vigene Biosciences, led by CEO Zairen Sun, right, and Chief Commercial Officer Jeffrey Hung, has been acquired. EMAN MOHAMMED

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company’s Board of Directors.

Go pakh your cahr, Boston. Grab some granola, California. It’s D.C.’s moment in life sciences. 

For years, the Washington metropolitan area has been one of the nation’s fastest-growing and largest life sciences markets. Growth during the pandemic and the market’s singular location are launching it into a whole other stratosphere. 

Image: ST. JOHN PROPERTIES’ MATT HOLBROOK AT RIVERSIDE TECH PARK IN FREDERICK. PHOTO: BY ST. JOHN PROPERTIES 

Entrepreneurs who require funding for their startup have long counted on self-accredited high net worth individuals (“angels”) to fill their needs, after friends and family, and before they qualify for institutional investments (“VCs”). The many crowd funding platforms on the Internet, led still by Kickstarter and IndieGoGo, were expected by many to put regular people in charge of funding new opportunities, and kill the need for angel groups.

Image: https://blog.startupprofessionals.com

Since 2005, the Small Business Capital Investment Incentive has generated early-stage funding for more than 200 Arizona businesses, including my company, Qwick. I moved from California to Arizona to launch Qwick, an on-demand staffing platform for the service industry, because I know that new companies need these early investments to succeed.

As Arizona lawmakers finalize the fiscal 2022 budget, they can support new businesses by extending this incentive that’s commonly known as the angel investor tax credit. The program has made a $1.38 billion economic impact over the past six years alone.